Home
/
SANGAMO THERAPEUTICS, INC
/
Financials
/
Quarterly
SANGAMO THERAPEUTICS, INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that SANGAMO THERAPEUTICS, INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$12.64M
May 10, 2018
Q3
2017
Sep 30, 2017
$11.81M
Nov 9, 2017
Q2
2017
Jun 30, 2017
$8.25M
Aug 9, 2017
Q1
2018
Mar 31, 2017
$3.43M
May 10, 2018
Q3
2017
Sep 30, 2016
$2.82M
Nov 9, 2017
Q2
2017
Jun 30, 2016
$3.70M
Aug 9, 2017
Q1
2017
Mar 31, 2016
$3.94M
May 10, 2017
Q3
2016
Sep 30, 2015
$8.57M
Oct 27, 2016
Q2
2016
Jun 30, 2015
$8.36M
Aug 4, 2016
Q1
2016
Mar 31, 2015
$13.49M
May 5, 2016
Q3
2015
Sep 30, 2014
$12.42M
Oct 30, 2015
Q2
2015
Jun 30, 2014
$10.39M
Aug 6, 2015
Q1
2015
Mar 31, 2014
$8.12M
Apr 28, 2015
Q3
2014
Sep 30, 2013
$5.71M
Oct 28, 2014
Q2
2014
Jun 30, 2013
$6.93M
Jul 29, 2014
Q1
2014
Mar 31, 2013
$4.62M
May 7, 2014
Q3
2013
Sep 30, 2012
$4.91M
Nov 4, 2013
Q2
2013
Jun 30, 2012
$4.57M
Aug 2, 2013
Q1
2013
Mar 31, 2012
$3.24M
May 9, 2013
Q3
2012
Sep 30, 2011
$1.86M
Nov 2, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$581.0K
Nov 6, 2025
Q2
2025
Jun 30, 2025
$18.31M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$6.44M
May 12, 2025
Q3
2025
Sep 30, 2024
$49.41M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$356.0K
Aug 7, 2025
Q1
2025
Mar 31, 2024
$481.0K
May 12, 2025
Q3
2024
Sep 30, 2023
$9.40M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$6.84M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$157.96M
May 9, 2024
Q3
2023
Sep 30, 2022
$26.46M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$29.38M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$28.23M
May 8, 2023
Q3
2022
Sep 30, 2021
$28.56M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$27.87M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$26.28M
May 5, 2022
Q3
2021
Sep 30, 2020
$57.76M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$21.55M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$13.08M
May 4, 2021
Q3
2020
Sep 30, 2019
$21.96M
Nov 4, 2020
Q2
2020
Jun 30, 2019
$17.55M
Aug 5, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($34.93M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($19.99M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($30.60M)
May 12, 2025
Q3
2025
Sep 30, 2024
$10.67M
Nov 6, 2025
Q2
2025
Jun 30, 2024
($36.13M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($49.09M)
May 12, 2025
Q3
2024
Sep 30, 2023
($104.16M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($114.51M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
$21.13M
May 9, 2024
Q1
2023
Dec 31, 2022
($192.30M)
May 8, 2023
Q3
2023
Sep 30, 2022
($53.16M)
Nov 1, 2023
Q2
2023
Jun 30, 2022
($43.17M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($43.98M)
May 8, 2023
Q1
2023
Dec 31, 2021
($178.30M)
May 8, 2023
Q3
2021
Sep 30, 2021
($47.69M)
Nov 4, 2021
Q2
2021
Jun 30, 2021
($47.17M)
Aug 5, 2021
Q1
2022
Mar 31, 2021
($45.93M)
May 5, 2022
Q3
2021
Sep 30, 2020
($1.55M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($35.93M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($42.91M)
May 4, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($35.55M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($17.86M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($29.63M)
May 12, 2025
Q3
2025
Sep 30, 2024
$10.63M
Nov 6, 2025
Q2
2025
Jun 30, 2024
($37.08M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($51.53M)
May 12, 2025
Q3
2024
Sep 30, 2023
($106.41M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($123.57M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
$18.03M
May 9, 2024
Q3
2023
Sep 30, 2022
($54.89M)
Nov 1, 2023
Q2
2023
Jun 30, 2022
($45.73M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($45.26M)
May 8, 2023
Q3
2022
Sep 30, 2021
($48.44M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($48.70M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($46.30M)
May 5, 2022
Q3
2021
Sep 30, 2020
($3.70M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($37.90M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($44.52M)
May 4, 2021
Q3
2020
Sep 30, 2019
($29.25M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($33.50M)
Aug 5, 2020